• Product nameAnti-Chd7 antibody
    See all Chd7 primary antibodies
  • Description
    Rabbit polyclonal to Chd7
  • Tested applicationsSuitable for: ICC, ICC/IF, WB, IHC-Pmore details
  • Species reactivity
    Reacts with: Mouse, Human
  • Immunogen

    An 18 amino acid synthetic peptide from near the N terminus of Human Chd7.

  • Positive control
    • SK-N-SH cell lysate



Our Abpromise guarantee covers the use of ab117522 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ICC Use a concentration of 5 µg/ml.
ICC/IF Use a concentration of 20 µg/ml.
WB Use a concentration of 1 - 2 µg/ml. Predicted molecular weight: 336 kDa.
IHC-P Use at an assay dependent concentration.


  • FunctionProbable transcription regulator.
  • Tissue specificityWidely expressed in fetal and adult tissues.
  • Involvement in diseaseDefects in CHD7 are a cause of CHARGE syndrome (CHARGES) [MIM:214800]. This syndrome, which is a common cause of congenital anomalies, is characterized by a non-random pattern of congenital anomalies including choanal atresia and malformations of the heart, inner ear, and retina.
    Genetic variations in CHD7 are associated with susceptibility to idiopathic scoliosis type 3 (IS3) [MIM:608765]. Idiopathic scoliosis (IS) is the most common spinal deformity in children.
    Defects in CHD7 are the cause of Kallmann syndrome type 5 (KAL5) [MIM:612370]. Kallmann syndrome is a disorder that associates hypogonadotropic hypogonadism and anosmia. Anosmia or hyposmia is related to the absence or hypoplasia of the olfactory bulbs and tracts. Hypogonadism is due to deficiency in gonadotropin-releasing hormone and probably results from a failure of embryonic migration of gonadotropin-releasing hormone-synthesizing neurons. In some patients other developmental anomalies can be present, which include renal agenesis, cleft lip and/or palate, selective tooth agenesis, and bimanual synkinesis. In some cases anosmia may be absent or inconspicuous.
    Defects in CHD7 are a cause of idiopathic hypogonadotropic hypogonadism (IHH) [MIM:146110]. IHH is defined as a deficiency of the pituitary secretion of follicle-stimulating hormone and luteinizing hormone, which results in the impairment of pubertal maturation and of reproductive function.
  • Sequence similaritiesBelongs to the SNF2/RAD54 helicase family.
    Contains 2 chromo domains.
    Contains 1 helicase ATP-binding domain.
    Contains 1 helicase C-terminal domain.
  • Post-translational
    Phosphorylated upon DNA damage, probably by ATM or ATR.
  • Cellular localizationNucleus.
  • Information by UniProt
  • Database links
  • Alternative names
    • ATP-dependent helicase CHD7 antibody
    • ATP-dependent helicase chromodomain helicase DNA binding protein 7 antibody
    • CHD-7 antibody
    • Chd7 antibody
    • CHD7_HUMAN antibody
    • Chromodomain helicase DNA binding protein 7 antibody
    • chromodomain helicase DNA binding protein 7 isoform CRA_e antibody
    • Chromodomain-helicase-DNA-binding protein 7 antibody
    • FLJ20357 antibody
    • FLJ20361 antibody
    • HH5 antibody
    • IS3 antibody
    • KAL5 antibody
    • KIAA1416 antibody
    see all

Anti-Chd7 antibody images

  • Immunofluorescence of Chd7 in mouse brain tissue with ab117522 at 20 ug/mL.
  • Lane 1 : Anti-Chd7 antibody (ab117522) at 1 µg/ml
    Lane 2 : Anti-Chd7 antibody (ab117522) at 2 µg/ml

    Lane 1 : SK-N-SH cell lysate
    Lane 2 : SK-N-SH cell lysate

    Lysates/proteins at 15 µg per lane.

    Predicted band size : 336 kDa
  • Immunohistochemistry of CHD7 in mouse brain tissue with ab117522 at 5 ug/mL.

References for Anti-Chd7 antibody (ab117522)

ab117522 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab117522.
Please use the links above to contact us or submit feedback about this product.